Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - r
16910
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Enginee
r
ed Mucosal-Associated Invariant T (MAIT) Cells and Methods of Making and Using Thereof (UCLA Case No. 2024-055)
UCLA
r
esearchers in the Department of Microbiology Immunology and Molecular Genetics have developed a novel platform and methodology for the production of mucosal-associated invariant T (MAIT) cells for therapeutic use in infectious diseases, autoimmune disorders, and cancer. BACKGROUND: Mucosal-associated invariant T (MAIT) cells are a subset of...
Published: 7/31/2025
|
Inventor(s):
Lili Yang
Keywords(s):
Category(s):
The
r
apeutics > Oncology
,
The
r
apeutics > Infectious Diseases
,
The
r
apeutics > Immunology And Immunotherapy
,
The
r
apeutics > Autoimmune
Telap
r
evir-derived Enterovirus D68 2A protease inhibitors are antiviral drug candidates
Published data fo
r
lead compounds, the telaprevir-derived 2Apro inhibitor Jun11762 and others, demonstrate substantial improvement over Telaprevir in plaque assay. See link to paper below. Invention Summary: The genus Enterovirus of Picornaviridae contains many significant pathogens related to human and mammalian diseases. Enterovirus D68...
Published: 7/31/2025
|
Inventor(s):
Jun Wang
,
Bin Tan
,
P
r
akash Jadhav
,
Kan Li
Keywords(s):
Antivi
r
al
,
Small molecules
Category(s):
Technology Classifications > Healthca
r
e & Life Sciences
,
Technology Classifications > Infectious Disease
,
Technology Classifications > The
r
apeutics
Fuma
r
amide SARS-CoV-2 papain-like protease inhibitors are antiviral drug candidates
Published data fo
r
lead compound, the fumaramide PLpro inhibitor Jun13728, demonstrate potent inhibition of SARS-CoV2 variants including nirmatrelvir-resistant mutant (light blue). Link to paper below. Invention Summary: The COVID-19 pandemic significantly accelerated the development of antiviral therapies and vaccines. Recent efforts for...
Published: 7/31/2025
|
Inventor(s):
Jun Wang
,
Bin Tan
,
P
r
akash Jadhav
,
Ahmadullah Ansa
r
i
,
F
r
ancesc Ruiz Figueras
,
Edwa
r
d Arnold
Keywords(s):
Category(s):
Technology Classifications > Healthca
r
e & Life Sciences
,
Technology Classifications > The
r
apeutics
Modula
r
protein degradation platform bypassing ubiquitination
Backg
r
ound Targeted protein degradation is rapidly emerging as a powerful therapeutic approach for eliminating disease-causing proteins in cancer, neurodegenerative conditions, autoimmune disorders, and viral infections. By removing, rather than inhibiting, harmful proteins, this strategy enables direct and sustained therapeutic effects....
Published: 7/31/2025
|
Inventor(s):
And
r
eas Matouschek
,
Amit Kuma
r
Singh Gautam
,
Ca
r
oline Davis
,
Logan Spalle
r
Keywords(s):
Category(s):
Life sciences > The
r
apeutics > Synthetic biology
,
Life sciences >
R
esearch tools > Tool/assay/screening platform
Mic
r
obial Functions and Molecules to Promote the Beneficial Effects of the Ketogenic Diet (UCLA Case No. 2022-122)
UCLA
r
esearchers in the Department of Integrative Biology and Physiology have successfully mapped the functional gut microbiota and specific metabolic molecules that promote relief from epilepsy through the ketogenic diet. BACKGROUND: Research supported by the National Institutes of Health has shown that the gut microbiome has tremendous impact on...
Published: 7/31/2025
|
Inventor(s):
Elaine Hsiao
Keywords(s):
Category(s):
The
r
apeutics > CNS and Neurology
Biocompatible photoenzymatic system fo
r
selective C–H fluorination
Backg
r
ound C–H fluorination plays a central role in pharmaceutical and agrochemical synthesis, as the introduction of fluorine often enhances a molecule's metabolic stability, potency, and bioavailability. Over 20% of approved drugs contain fluorinated functional groups, underscoring the demand for efficient and selective fluorination methods....
Published: 7/31/2025
|
Inventor(s):
Yi Lu
,
Yu Zhou
Keywords(s):
Category(s):
Life sciences > Metabolic enginee
r
ing
OPG153-based vaccine fo
r
targeted mpox immunization
Backg
r
ound The global re-emergence of monkeypox virus (MPXV) has created a critical need for effective and well-tolerated vaccines to prevent infection, limit disease severity, and reduce transmission. As an orthopoxvirus related to smallpox, mpox presents a unique public health challenge, especially for immunocompromised populations. Current...
Published: 7/31/2025
|
Inventor(s):
Jason McLellan
,
Ling Zhou
,
Emily
R
undlet
,
Emanuele And
r
eano
,
R
ino Rappuoli
,
Ida Paciello
,
Giulia
R
ealini
,
Fede
r
ica Perrone
Keywords(s):
Category(s):
Life sciences > The
r
apeutics > Vaccines
I
r
reversible DGKα inhibitors for enhanced T‑cell activation in cancer immunotherapy
Backg
r
ound Cancer immunotherapy seeks to harness the immune system to target and eliminate malignant cells. However, immune suppression within the tumor microenvironment poses a major challenge, blunting T-cell activation and allowing cancer cells to evade immune detection. Diacylglycerol Kinase α (DGKα) is a key enzyme that suppresses...
Published: 7/31/2025
|
Inventor(s):
Ku-Lung Hsu
,
Minhaj Shaikh
,
Adam Libby
,
Su
r
ya Pravo Mookherjee
Keywords(s):
Category(s):
Life sciences > The
r
apeutics > Formulation
Quinoline-de
r
ived SARS-CoV-2 papain-like protease inhibitors are oral antiviral drug candidates
A lead compound, the quinoline-de
r
ived PLpro inhibitor Jun13296, demonstrates substantial protection against SARS-CoV-2 infection and adverse clinical outcomes. Invention Summary: The COVID-19 pandemic significantly accelerated the development of antiviral therapies and vaccines. Recent efforts for research to support pandemic preparedness...
Published: 7/31/2025
|
Inventor(s):
Jun Wang
,
P
r
akash Jadhav
,
Bin Tan
,
Haozhou Tan
Keywords(s):
Antivi
r
al
Category(s):
Technology Classifications > COVID-19
,
Technology Classifications > Healthca
r
e & Life Sciences
,
Technology Classifications > Infectious Disease
,
Technology Classifications > The
r
apeutics
Specific inhibito
r
s to mitigate mu opioid‐induced side‐effects without compromising analgesia
P
r
eliminary data shows that the inhibitor significantly mitigates morphine tolerance in a mouse study Invention Summary: Mu opioids such as morphine and fentanyl are commonly used for pain management but can lead to tolerance, addiction, and opioid use disorder. Current therapeutic solutions for these adverse conditions include buprenorphine,...
Published: 7/31/2025
|
Inventor(s):
Yingxian Pan
Keywords(s):
Category(s):
Technology Classifications > Healthca
r
e & Life Sciences
,
Technology Classifications
,
Technology Classifications > The
r
apeutics
1
2
3
4
5
6
7
8
9
10
...